We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Intrexon Corporation Initiates Phase 1b Clinical Trial in Advanced Melanoma
News

Intrexon Corporation Initiates Phase 1b Clinical Trial in Advanced Melanoma

Intrexon Corporation Initiates Phase 1b Clinical Trial in Advanced Melanoma
News

Intrexon Corporation Initiates Phase 1b Clinical Trial in Advanced Melanoma

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Intrexon Corporation Initiates Phase 1b Clinical Trial in Advanced Melanoma"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Intrexon Corporation announces that it has initiated treatment of the first patient in its Phase 1b clinical trial of INcell-1001/AD-1001 in patients with Stage III/IV melanoma. INcell-1001/AD-1001 is Intrexon’s most advanced immunomodulatory therapy. INcell-1001 is intended to control and enhance the immune-modulating performance of dendritic cells to treat solid tumor cancers.

The trial is an open-label, dose-escalation study evaluating the safety, tolerance, transgene function, pharmacokinetics and immunological effects of intratumoral injection of transduced dendritic cells (INcell-1001). INcell-1001 has been engineered for inducible expression of human Interleukin 12 (hIL-12) using regimented dosing of an orally administered small molecule (AD-1001).

The primary endpoints of the Phase 1b study are the safety and tolerability of INcell-1001 induced by escalating doses of the activator AD-1001. Secondary endpoints include the pharmacodynamics of the AD-1001/INcell-1001 combination, as represented by hIL-12 expression levels, plus anti-tumor activity, as represented by cellular immune responses within the target tumor, draining lymph nodes and peripheral circulation.
Advertisement